Literature DB >> 16709847

Evidence for a domain-swapped CD4 dimer as the coreceptor for binding to class II MHC.

Akiko Maekawa1, Bryan Schmidt, Barbara Fazekas de St Groth, Yves-Henri Sanejouand, Philip J Hogg.   

Abstract

CD4 is a coreceptor for binding of T cells to APC and the primary receptor for HIV. The disulfide bond in the second extracellular domain (D2) of CD4 is reduced on the cell surface, which leads to formation of disulfide-linked homodimers. A large conformational change must take place in D2 to allow for formation of the disulfide-linked dimer. Domain swapping of D2 is the most likely candidate for the conformational change leading to formation of two disulfide-bonds between Cys130 in one monomer and Cys159 in the other one. Mild reduction of the extracellular part of CD4 resulted in formation of disulfide-linked dimers, which supports the domain-swapped model. The functional significance of dimer formation for coreceptor function was tested using cells expressing wild-type or disulfide-bond mutant CD4. Eliminating the D2 disulfide bond markedly impaired CD4's coreceptor function. Modeling of the complex of the TCR and domain-swapped CD4 dimer bound to class II MHC and Ag supports the domain-swapped dimer as the immune coreceptor. The known involvement of D4 residues Lys318 and Gln344 in dimer formation is also accommodated by this model. These findings imply that disulfide-linked dimeric CD4 is the preferred coreceptor for binding to APC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16709847     DOI: 10.4049/jimmunol.176.11.6873

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Crystal structure of a complete ternary complex of T-cell receptor, peptide-MHC, and CD4.

Authors:  Yiyuan Yin; Xin Xiang Wang; Roy A Mariuzza
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-19       Impact factor: 11.205

2.  Reduced monomeric CD4 is the preferred receptor for HIV.

Authors:  Lisa J Matthias; Iman Azimi; Catherine A Tabrett; Philip J Hogg
Journal:  J Biol Chem       Date:  2010-10-25       Impact factor: 5.157

Review 3.  From structure to redox: The diverse functional roles of disulfides and implications in disease.

Authors:  Tyler J Bechtel; Eranthie Weerapana
Journal:  Proteomics       Date:  2017-03       Impact factor: 3.984

Review 4.  Targeting allosteric disulphide bonds in cancer.

Authors:  Philip J Hogg
Journal:  Nat Rev Cancer       Date:  2013-05-10       Impact factor: 60.716

5.  Engineered single human CD4 domains as potent HIV-1 inhibitors and components of vaccine immunogens.

Authors:  Weizao Chen; Yang Feng; Rui Gong; Zhongyu Zhu; Yanping Wang; Qi Zhao; Dimiter S Dimitrov
Journal:  J Virol       Date:  2011-06-29       Impact factor: 5.103

6.  Disulfide bond that constrains the HIV-1 gp120 V3 domain is cleaved by thioredoxin.

Authors:  Iman Azimi; Lisa J Matthias; Rob J Center; Jason W H Wong; Philip J Hogg
Journal:  J Biol Chem       Date:  2010-10-13       Impact factor: 5.157

7.  Labile disulfide bonds are common at the leucocyte cell surface.

Authors:  Clive Metcalfe; Peter Cresswell; Laura Ciaccia; Benjamin Thomas; A Neil Barclay
Journal:  Open Biol       Date:  2011-11       Impact factor: 6.411

8.  Disulfide reduction in CD4 domain 1 or 2 is essential for interaction with HIV glycoprotein 120 (gp120), which impairs thioredoxin-driven CD4 dimerization.

Authors:  Nichole Cerutti; Mark Killick; Vinesh Jugnarain; Maria Papathanasopoulos; Alexio Capovilla
Journal:  J Biol Chem       Date:  2014-02-18       Impact factor: 5.157

9.  The superior folding of a RANTES analogue expressed in lactobacilli as compared to mammalian cells reveals a promising system to screen new RANTES mutants.

Authors:  Massimiliano Secchi; Qiang Xu; Paolo Lusso; Luca Vangelista
Journal:  Protein Expr Purif       Date:  2009-06-30       Impact factor: 1.650

10.  Increased synapse formation obtained by T cell epitopes containing a CxxC motif in flanking residues convert CD4+ T cells into cytolytic effectors.

Authors:  Vincent A Carlier; Luc VanderElst; Wim Janssens; Marc G Jacquemin; Jean-Marie R Saint-Remy
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.